Novogen & Sante Naturelle (Canada) Enter Into a Patent License Agreement and Settle Patent Infringement Case
January 18 2007 - 4:06PM
PR Newswire (US)
STAMFORD, Conn., Jan. 18 /PRNewswire-FirstCall/ -- Novogen Limited
(NASDAQ:NVGN), the world leader in isoflavone research, has settled
for an undisclosed amount and terms, its allegations of patent
infringement against Sante Naturelle A.G. Ltee ("Sante"). Novogen
had alleged that certain menopause products sold by Sante infringed
Novogen's Canadian patent for health supplements containing
isoflavones. (Patent No. 2136233). In addition to an undisclosed
monetary settlement Sante has entered into a licensing agreement
with Novogen. This agreement grants Sante a license under Canadian
Patent No. 2136233 and will enable Sante to continue to manufacture
and sell certain menopause supplements containing isoflavones
derived from sources other than soy. The Chief Executive of
Novogen, Mr. Christopher Naughton, said Novogen is dedicated to the
development of isoflavonoid technology, protected by intellectual
property, in both the dietary supplement and prescription
pharmaceutical arenas. "The resolution of this matter is another
significant recognition of the value of our isoflavone patent
portfolio and adds to a history of several similar settlements in
North America in recent years," Mr. Christopher Naughton said.
Novogen manages its international research and development programs
that use the expertise and clinical research capabilities of
universities and hospitals in the U.S., Australia and other key
international locations. Novogen's leading dietary supplement
products are Promensil, for the relief of menopausal symptoms, and
Trinovin(TM), for prostate health. These brands are marketed
directly by Novogen in Australia, Canada and Europe, and under
licence to Natrol Inc in the USA. About Novogen Novogen Limited is
an Australian biotechnology company that has patented isoflavone
technology for the treatment and prevention of degenerative
diseases and disorders. Over the past ten years, Novogen has
conducted the largest and most comprehensive isoflavone clinical
testing programs in the world. Novogen is involved in drug
discovery and product development for disorders that are commonly
associated with aging and coordinates an international clinical
research and development program with external collaborators,
hospitals and universities. Novogen's investigational anti-cancer
drug phenoxodiol is currently in Phase III human clinical trials in
the U.S., Europe and Australia. The rights to commercialize this
drug are licensed to the Company's majority owned, Marshall
Edwards, Inc., (NASDAQ:MSHL). More information can be found at
http://www.novogen.com/ and http://www.marshalledwardsinc.com/.
Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that our actual results
could differ materially from those contained in the forward-looking
statements, which are based on management's current expectations
and are subject to a number of risks and uncertainties, including,
but not limited to, our failure to successfully commercialize our
product candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability
to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products; competitive
factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any additional
required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements. DATASOURCE:
Novogen Limited CONTACT: Mr. Christopher Naughton, Managing
Director of Novogen Limited, + 011 61 (02) 9878 0088; or David
Sheon of SciWords, LLC, +1-202-518-6321, for Novogen Limited Web
site: http://www.novogen.com/ http://www.marshalledwardsinc.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024